Hyperion Therapeutics (HPTX) to Resume Trading at 3:20pm ET
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Hyperion Therapeutics (HPTX) Resumes; Shares Move Lower
February 1, 2013 3:21 PM ESTHyperion Therapeutics (NASDAQ: HPTX) resumes trading, shares are dipping at the start.... More
Hyperion Therapeutics (HPTX) RAVICTI Receives FDA Approval
February 1, 2013 3:02 PM ESTHyperion Therapeutics, Inc. (Nasdaq: HPTX) announced that the U.S. Food and Drug Administration (FDA) has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013.
Separately, Hyperion announced it has received notification from the U.S. Patent & Trademark Office (USPTO) of... More
Hyperion Therapeutics (HPTX) halted, news pending
February 1, 2013 12:17 PM ESTHyperion Therapeutics (NASDAQ: HPTX) halted, news pending... More
